Abu Za'nouneh Faris Jamal, Ababneh Obada, Schinke Carolina, Thanendrarajan Sharmilan, Zangari Maurizio, Shaughnessy John D, Zhan Fenghuang, van Rhee Frits, Al Hadidi Samer
Faculty of Medicine Jordan University Of Science and Technology Irbid Jordan.
Myeloma Institute University of Arkansas for Medical Sciences Little Rock Arkansas USA.
EJHaem. 2023 Mar 28;4(2):454-458. doi: 10.1002/jha2.675. eCollection 2023 May.
The definition of high-risk multiple myeloma (HRMM) is evolving. Use of a clear definition of HRMM in clinical trials was not previously studied. We explored the definition of HRMM in completed phase III clinical trials. There is extreme variability in the definition and cutoffs used to define HRMM, with a significant number of studies lacking a clear definition. Our study provides a quantification of the variability in defining HRMM and suggests a need to better define HRMM in future clinical trials to enable more consistent treatment recommendations.
高危多发性骨髓瘤（HRMM）的定义正在不断演变。此前尚未研究过在临床试验中使用明确的HRMM定义。我们在已完成的III期临床试验中探讨了HRMM的定义。用于定义HRMM的定义和临界值存在极大差异，大量研究缺乏明确的定义。我们的研究对定义HRMM的变异性进行了量化，并表明有必要在未来的临床试验中更好地定义HRMM，以便能给出更一致的治疗建议。
